JP2004527492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527492A5 JP2004527492A5 JP2002567293A JP2002567293A JP2004527492A5 JP 2004527492 A5 JP2004527492 A5 JP 2004527492A5 JP 2002567293 A JP2002567293 A JP 2002567293A JP 2002567293 A JP2002567293 A JP 2002567293A JP 2004527492 A5 JP2004527492 A5 JP 2004527492A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- tremor
- composition
- group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010044565 Tremor Diseases 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 208000016285 Movement disease Diseases 0.000 claims 9
- 206010003591 Ataxia Diseases 0.000 claims 7
- 206010010904 Convulsion Diseases 0.000 claims 6
- 206010034010 Parkinsonism Diseases 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000006517 essential tremor Diseases 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 206010008748 Chorea Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000012601 choreatic disease Diseases 0.000 claims 3
- 230000036461 convulsion Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010022520 Intention tremor Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010073211 Postural tremor Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000002566 clonic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168301P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/005542 WO2002067926A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating movement disorders |
| US10/081,501 US6589985B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527492A JP2004527492A (ja) | 2004-09-09 |
| JP2004527492A5 true JP2004527492A5 (enExample) | 2005-12-22 |
Family
ID=26765643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567293A Pending JP2004527492A (ja) | 2001-02-27 | 2002-02-21 | 運動障害の予防もしくは治療における使用のためのカルバメート化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6589985B2 (enExample) |
| EP (1) | EP1411917B1 (enExample) |
| JP (1) | JP2004527492A (enExample) |
| KR (1) | KR100858232B1 (enExample) |
| CN (1) | CN1262272C (enExample) |
| AR (1) | AR033426A1 (enExample) |
| AT (1) | ATE369130T1 (enExample) |
| AU (1) | AU2002247204B2 (enExample) |
| BR (1) | BR0207831A (enExample) |
| CA (1) | CA2439478C (enExample) |
| CY (1) | CY1106924T1 (enExample) |
| CZ (1) | CZ20032299A3 (enExample) |
| DE (1) | DE60221670T2 (enExample) |
| DK (1) | DK1411917T3 (enExample) |
| ES (1) | ES2291454T3 (enExample) |
| HU (1) | HUP0303344A3 (enExample) |
| IL (2) | IL157592A0 (enExample) |
| MX (1) | MXPA03007719A (enExample) |
| MY (1) | MY157373A (enExample) |
| NO (1) | NO20033803L (enExample) |
| NZ (1) | NZ551954A (enExample) |
| PL (1) | PL364679A1 (enExample) |
| PT (1) | PT1411917E (enExample) |
| RS (1) | RS50676B (enExample) |
| RU (1) | RU2294739C2 (enExample) |
| TW (1) | TWI331524B (enExample) |
| WO (1) | WO2002067926A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ523851A (en) * | 2000-07-21 | 2004-09-24 | Ortho Mcneil Pharm Inc | A method for use of carbamate enantiomers in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| WO2002067925A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| DE60232796D1 (de) | 2001-07-16 | 2009-08-13 | Ortho Mcneil Pharm Inc | Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen |
| WO2006133393A1 (en) | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
| EP1928451B1 (en) * | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| WO2008054984A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica, N.V. | Treatment of pervasive developmental disorders |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) * | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| EP2968210B1 (en) * | 2013-03-12 | 2024-09-11 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy |
| US9907776B2 (en) | 2013-03-12 | 2018-03-06 | Bio-Pharm Solutions, Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| US11033531B2 (en) * | 2016-12-14 | 2021-06-15 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome |
| JP2020528075A (ja) | 2017-06-02 | 2020-09-17 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 過度の眠気を処置するための方法および組成物 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| CN115996905A (zh) * | 2020-08-31 | 2023-04-21 | 生物药品解决方案有限公司 | 用于预防或治疗神经退行性疾病的氨基甲酸苯基烷基酯化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
-
2002
- 2002-02-21 US US10/081,501 patent/US6589985B2/en not_active Expired - Fee Related
- 2002-02-21 RU RU2003128985/14A patent/RU2294739C2/ru not_active IP Right Cessation
- 2002-02-21 BR BR0207831-7A patent/BR0207831A/pt not_active Application Discontinuation
- 2002-02-21 DK DK02714978T patent/DK1411917T3/da active
- 2002-02-21 CN CNB028089243A patent/CN1262272C/zh not_active Expired - Fee Related
- 2002-02-21 ES ES02714978T patent/ES2291454T3/es not_active Expired - Lifetime
- 2002-02-21 WO PCT/US2002/005542 patent/WO2002067926A1/en not_active Ceased
- 2002-02-21 DE DE60221670T patent/DE60221670T2/de not_active Expired - Lifetime
- 2002-02-21 HU HU0303344A patent/HUP0303344A3/hu unknown
- 2002-02-21 PL PL02364679A patent/PL364679A1/xx not_active Application Discontinuation
- 2002-02-21 JP JP2002567293A patent/JP2004527492A/ja active Pending
- 2002-02-21 NZ NZ551954A patent/NZ551954A/en unknown
- 2002-02-21 CA CA2439478A patent/CA2439478C/en not_active Expired - Fee Related
- 2002-02-21 MX MXPA03007719A patent/MXPA03007719A/es active IP Right Grant
- 2002-02-21 AU AU2002247204A patent/AU2002247204B2/en not_active Ceased
- 2002-02-21 AT AT02714978T patent/ATE369130T1/de active
- 2002-02-21 EP EP02714978A patent/EP1411917B1/en not_active Expired - Lifetime
- 2002-02-21 RS YUP-677/03A patent/RS50676B/sr unknown
- 2002-02-21 KR KR1020037011271A patent/KR100858232B1/ko not_active Expired - Fee Related
- 2002-02-21 CZ CZ20032299A patent/CZ20032299A3/cs unknown
- 2002-02-21 PT PT02714978T patent/PT1411917E/pt unknown
- 2002-02-21 IL IL15759202A patent/IL157592A0/xx unknown
- 2002-02-27 AR ARP020100698A patent/AR033426A1/es unknown
- 2002-02-27 MY MYPI20020692A patent/MY157373A/en unknown
- 2002-02-27 TW TW091103503A patent/TWI331524B/zh not_active IP Right Cessation
-
2003
- 2003-08-26 NO NO20033803A patent/NO20033803L/no not_active Application Discontinuation
- 2003-08-26 IL IL157592A patent/IL157592A/en not_active IP Right Cessation
-
2007
- 2007-10-10 CY CY20071101301T patent/CY1106924T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527492A5 (enExample) | ||
| JP2004517087A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| RU2003128985A (ru) | Производные карбамата для применения для предупреждения или лечения расстройств движений | |
| JP2005511698A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| IL189003A0 (en) | Methods for treating substance-related disorders | |
| JP2004525905A5 (enExample) | ||
| JPWO2023195529A5 (enExample) | ||
| JP2005511697A5 (enExample) | ||
| JP2004533415A5 (enExample) | ||
| RU2003128984A (ru) | Производные карбаматов для использования для лечения боли | |
| WO2007008562A3 (en) | Carbamate compounds for use in treating neurodegenerative disorders | |
| NO20033799L (no) | Karbamatforbindelser for anvendelse ved prevensjon eller terapi av bipolarelidelser | |
| CA2439475A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| JP2004523556A5 (enExample) | ||
| MA27605A1 (fr) | Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel | |
| RU2003128983A (ru) | Производные карбаматов для предотвращения или лечения психотических нарушений | |
| JP2007518798A5 (enExample) | ||
| EA202191075A1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| JP2005517634A5 (enExample) | ||
| JP2005516952A5 (enExample) | ||
| JP2006524677A5 (enExample) | ||
| JP2009509927A5 (enExample) |